Works matching DE "BORTEZOMIB"

Results: 1590

Bortezomib as a Potential Treatment for Recurrent Autoimmune Hepatitis Following Pediatric Liver Transplantation.

Published in:

Pediatric Transplantation, 2025, v. 29, n. 4, p. 1, doi. 10.1111/petr.70082

By:

Semash, Konstantin;
Dzhanbekov, Timur;
Nasirov, Mansur;
Monakhov, Artem;
Gadzhieva, Patimat

Publication type:

Article

Cardiovascular Toxicity of Biologic Agents for Cancer Therapy.

Published in:

Oncology (08909091), 2014, v. 28, n. 6, p. 482

By:

BHAVE, MANALI;
AKHTER, NAUSHEEN;
ROSEN, STEVEN T.

Publication type:

Article

Protective effects of agomelatine on testicular damage caused by bortezomib.

Published in:

Biotechnic & Histochemistry, 2017, v. 92, n. 8, p. 552, doi. 10.1080/10520295.2017.1350748

By:

Akaras, N;
Bal, T;
Atilay, H;
Selli, J;
Halici, MB

Publication type:

Article

Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.

Published in:

Veterinary & Comparative Oncology, 2024, v. 22, n. 1, p. 96, doi. 10.1111/vco.12957

By:

Prevedel, Nicholas E.;
Mee, Miles W.;
Wood, Geoffrey A.;
Coomber, Brenda L.

Publication type:

Article

Total Synthesis of Syringolin A and Improvement of Its Biological Activity.

Published in:

Angewandte Chemie, 2014, v. 126, n. 19, p. 4936, doi. 10.1002/ange.201402428

By:

Chiba, Takuya;
Hosono, Hidetaka;
Nakagawa, Koji;
Asaka, Masahiro;
Takeda, Hiroshi;
Matsuda, Akira;
Ichikawa, Satoshi

Publication type:

Article

First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.

Published in:

European Journal of Clinical Pharmacology, 2016, v. 72, n. 3, p. 257, doi. 10.1007/s00228-015-1998-5

By:

Kuhr, Kathrin;
Wirth, Daniel;
Srivastava, Kunal;
Lehmacher, Walter;
Hellmich, Martin

Publication type:

Article

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.

Published in:

European Journal of Clinical Pharmacology, 2016, v. 72, n. 2, p. 153, doi. 10.1007/s00228-015-1967-z

By:

Mu, Song;
Kuroda, Yoshiaki;
Shibayama, Hirohiko;
Hino, Masayuki;
Tajima, Takeshi;
Corrado, Claudia;
Lin, Rong;
Waldron, Edward;
Binlich, Florence;
Suzuki, Kenshi

Publication type:

Article

Single-center clinical efficacy analysis of 16 cases of primary light chain cardiac amyloidosis including stage IIIb patients.

Published in:

Clinical & Experimental Medicine, 2025, v. 25, n. 1, p. 1, doi. 10.1007/s10238-025-01616-z

By:

Wang, Jing;
Ye, Shaojie;
Guo, Huimei;
Zhao, Songying;
Liu, Jia;
Zhang, JiangBo;
Xu, Jianmei;
Su, Xi;
Hua, Luoming;
Xue, Hua

Publication type:

Article

Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs.

Published in:

Clinical & Experimental Medicine, 2024, v. 24, n. 1, p. 1, doi. 10.1007/s10238-024-01445-6

By:

Gu, Xinyuan;
Tang, Wenjiao;
Zhang, Li;
Zheng, Yuhuan;
Pan, Ling;
Niu, Ting

Publication type:

Article

Profilin 1 induces drug resistance by downregulating CD138 expression via autophagy in multiple myeloma.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02036-x

By:

Wang, Ya;
Dai, ZiYu;
Xiao, Shengying;
Zeng, Furen;
Lu, YiChen

Publication type:

Article

Anti-tumor effect of dandelion flavone on multiple myeloma cells and its mechanism.

Published in:

Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01076-z

By:

Gui, Hua;
Fan, Xiaohong

Publication type:

Article

HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells.

Published in:

NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00422-8

By:

Lyu, Hui;
Hou, Defu;
Liu, Hao;
Ruan, Sanbao;
Tan, Congcong;
Wu, Jiande;
Hicks, Chindo;
Liu, Bolin

Publication type:

Article

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus.

Published in:

Global & Regional Health Technology Assessment, 2021, v. 8, n. 1, p. 80, doi. 10.33393/grhta.2021.2245

By:

Mario, Boccadoro;
Patrizia, Berto;
Sara, Bringhen;
Elena, Zamagni;
Patrizia, Tosi;
Nicola, Cascavilla;
Nicola, Giuliani;
Donato, Mannina;
Renato, Zambello;
Francesca, Patriarca;
Vittorio, Montefusco;
Mariella, Grasso;
Francesco, Di Raimondo;
Massimo, Offidani;
Maria Teresa, Petrucci;
Pellegrino, Musto

Publication type:

Article

FDA Approves Daratumumab and Hyaluronidase-Fihj With Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Published in:: ONS Voice, 2024, p. 1
Publication type:: Article

Impact of CD34/CD309 expression in circulating endothelial progenitor cells on prognosis and response to bortezomib therapy in multiple myeloma.

Published in:

Journal of Immunoassay & Immunochemistry, 2024, v. 45, n. 5, p. 481, doi. 10.1080/15321819.2024.2388614

By:

ElMenshawy, Nadia;
Ibrahim Fouda, Manal;
Mofreh, Mohamed;
Hisham El-Etriby, Heba;
O Elnenaei, Manal;
Eissa, Mohamed

Publication type:

Article

Impact of adding clarithromycin in multiple myeloma patients on outcome and overall survival.

Published in:

Egyptian Journal of Haematology, 2024, v. 49, n. 3, p. 325, doi. 10.4103/ejh.ejh_85_22

By:

Khalifa, Ibtesam M.;
Azzazi, Mohamed;
Moussa, Mohamed M.;
El-Salakawy, Walaa A.;
Hassan, Ahmed H.;
Abbas, Rana Z.

Publication type:

Article

Relation of junctional adhesion molecule-a in multiple myeloma patients with possible prognostic factors.

Published in:

Egyptian Journal of Haematology, 2023, v. 48, n. 2, p. 201, doi. 10.4103/ejh.ejh_55_23

By:

Shaaban, Ingy Ossama Ahmed;
Sultan, Hala K.;
Sultan, Magda M.;
El Gammal, Maha M. A.;
Balbaa, Ola A.

Publication type:

Article

Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2023, v. 132, n. 4, p. 297, doi. 10.1111/bcpt.13832

By:

Liao, Yu;
Hu, Kejun;
Liu, Wangwang;
Wang, Wei;
Qiu, Huanhuan;
Pan, Shumin;
Lv, Qi;
Xu, Guanglin

Publication type:

Article

The effects of bortezomib alone or in combination with 5-fluorouracil on proliferation and apoptosis of choriocarcinoma cells.

Published in:

European Journal of Gynaecological Oncology, 2016, v. 37, n. 5, p. 627, doi. 10.12892/ejgo3021.2016

By:

Wang, H. F.;
Tong, Y.;
Liu, L.;
Liu, H. P.;
Li, C. D.;
Liu, Q. R.

Publication type:

Article

Bortezomib treatment for severe refractory anti‐NMDA receptor encephalitis.

Published in:

Annals of Clinical & Translational Neurology, 2018, v. 5, n. 5, p. 598, doi. 10.1002/acn3.557

By:

Shin, Yong‐Won;
Lee, Soon‐Tae;
Kim, Tae‐Joon;
Jun, Jin‐Sun;
Chu, Kon

Publication type:

Article

Evaluating the Use of Bortezomib and Eculizumab in Desensitization of Transplant Patients.

Published in:

2014

By:

Kwiatkowski, Matthew;
Welch, Patrick;
McComb, Jennifer;
Shepler, Brian

Publication type:

Journal Article

Impact of bortezomib on 1q21+ in multiple myeloma: A meta-analysis of treatment outcomes and prognostic implications.

Published in:

Oncology Letters, 2025, v. 29, n. 1, p. N.PAG, doi. 10.3892/ol.2024.14764

By:

Zheng, Xiaona;
Lin, Siyu;
Lu, Kejie;
Hou, Jian;
Liu, Tingting

Publication type:

Article

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib.

Published in:

Oncology Letters, 2022, v. 24, n. 1, p. N.PAG, doi. 10.3892/ol.2022.13326

By:

Wu, Cuicui

Publication type:

Article

Transient receptor potential channels in multiple myeloma.

Published in:

Oncology Letters, 2022, v. 23, n. 4, p. N.PAG, doi. 10.3892/ol.2022.13228

By:

Meng, Lingjun;
Gu, Guiying;
Bi, Lintao

Publication type:

Article

Effects of a combined therapy of bortezomib and ionizing radiation on chondrosarcoma three-dimensional spheroid cultures.

Published in:

Oncology Letters, 2021, v. 21, n. 6, p. N.PAG, doi. 10.3892/ol.2021.12689

By:

Lohberger, Birgit;
Glaenzer, Dietmar;
Eck, Nicole;
Steinecker-Frohnwieser, Bibiane;
Leithner, Andreas;
Rinner, Beate;
Kerschbaum-Gruber, Sylvia;
Georg, Dietmar

Publication type:

Article

Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells.

Published in:

Oncology Letters, 2021, v. 21, n. 2, p. 1, doi. 10.3892/ol.2020.12370

By:

LEI JIANG;
YI-MING ZHAO;
MING-ZHEN YANG

Publication type:

Article

Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β-catenin signaling pathway.

Published in:

Oncology Letters, 2020, v. 20, n. 2, p. 1295, doi. 10.3892/ol.2020.11678

By:

Dai, Yanling;
Guo, Xiaomin;
Yang, Chunyan

Publication type:

Article

Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.

Published in:

Oncology Letters, 2019, v. 17, n. 4, p. 3719

By:

Yuan, Ting;
Zhang, Feng;
Zhou, Xiangxiang;
Li, Ying;
Zhang, Ya;
Xu, Yangyang;
Wang, Xin

Publication type:

Article

Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation.

Published in:

Oncology Letters, 2018, v. 16, n. 5, p. 5655, doi. 10.3892/ol.2018.9365

By:

Wang, Huan;
Zhou, Xin;
Zhu, Jian-Wei;
Ye, Jian-Nan;
Guo, Hong-Feng;
Sun, Chao

Publication type:

Article

Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report.

Published in:

2017

By:

Tao Wu;
Jinmao Zhou;
Cunbang Wang;
Binbin Wang;
Shuting Zhang;
Hai Bai

Publication type:

Case Study

Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.

Published in:

Oncology Letters, 2017, v. 13, n. 5, p. 3803, doi. 10.3892/ol.2017.5920

By:

NORIYOSHI IRIYAMA;
KATSUHIRO MIURA;
YOSHIHIRO HATTA;
SUMIKO KOBAYASHI;
YOSHIHITO UCHINO;
DAISUKE KURITA;
HITOMI SAKAGAMI;
HIROMICHI TAKAHASHI;
MASASHI SAKAGAMI;
YUJIN KOBAYASHI;
MASARU NAKAGAWA;
SHIMON OHTAKE;
YOSHIKAZU IIZUKA;
MASAMI TAKEI

Publication type:

Article

Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.

Published in:

Oncology Letters, 2017, v. 13, n. 2, p. 647, doi. 10.3892/ol.2016.5472

By:

JIANG-HUA DING;
LI-YA YUAN;
GUO-AN CHEN

Publication type:

Article

Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report.

Published in:

2016

By:

JUNXUN LI;
JIEYU ZHAN;
FAN ZHANG;
ZHUANGJIAN YE;
JUAN OUYANG

Publication type:

Case Study

Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.

Published in:

Oncology Letters, 2016, v. 11, n. 5, p. 3179, doi. 10.3892/ol.2016.4340

By:

ARAS, BEKIR;
YERLIKAYA, AZMI

Publication type:

Article

Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature.

Published in:

2016

By:

HUA-PING DU;
QIAN-QIAN YANG;
YE ZHANG

Publication type:

Case Study

Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.

Published in:

2016

By:

JINGBO LI;
SHUDA CHEN;
YINGHONG HU;
JING CAI

Publication type:

Case Study

Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report.

Published in:

Oncology Letters, 2015, v. 10, n. 5, p. 3064, doi. 10.3892/ol.2015.3634

By:

XINGBIN DAI;
XUEMEI SUN;
HAIWEN NI;
XUEJUN ZHU

Publication type:

Article

Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation.

Published in:

Oncology Letters, 2015, v. 10, n. 4, p. 2192, doi. 10.3892/ol.2015.3545

By:

ABD-AZIZ, NORAINI;
STANBRIDGE, ERIC J.;
SHAFEE, NORAZIZAH

Publication type:

Article

Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma.

Published in:

Oncology Letters, 2015, v. 10, n. 2, p. 1171, doi. 10.3892/ol.2015.3294

By:

WEIWEI ZHOU;
GUANGYU AN;
YUAN JIAN;
HUAN GUO;
WENMING CHEN

Publication type:

Article

Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells.

Published in:

Oncology Letters, 2015, v. 10, n. 1, p. 560, doi. 10.3892/ol.2015.3250

By:

KONAC, ECE;
VAROL, NURAY;
KILICCIOGLU, ILKER;
BILEN, CENK Y.

Publication type:

Article

Partial remission of acute myeloid leukemia complicating multiple myeloma following COAP chemotherapy: A case report.

Published in:

Oncology Letters, 2015, v. 9, n. 3, p. 1313, doi. 10.3892/ol.2015.2867

By:

MAN SHEN;
WAN-JUN SUN;
ZHONG-XIA HUANG;
JIA-JIA ZHANG;
NA AN- XIN LI

Publication type:

Article

A phase 0 analysis of ixazomib in patients with glioblastoma.

Published in:

Molecular & Clinical Oncology, 2020, v. 13, n. 5, p. N.PAG, doi. 10.3892/mco.2020.2114

By:

Quillin, Joseph;
Patel, Rikesh;
Herzberg, Eric;
Alton, Denny;
Bikzhanova, Galina;
Geisler, Lisa;
Olson, Jeffrey

Publication type:

Article

Diagnostic and treatment hurdles in plasma cell myeloma with t(11;14) translocation: A case report.

Published in:

2018

By:

Kong, Shun Yin;
Lam, Wing Kit;
Li, Ka Shu;
Yeung, Ka Pik;
Ha, Chung Yin;
Lai, Ho Kei;
Chan, Hay Nun;
Yeung, Yiu Ming;
Yip, Sze Fai

Publication type:

Case Study

Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature.

Published in:

Molecular & Clinical Oncology, 2017, v. 7, n. 4, p. 667, doi. 10.3892/mco.2017.1366

By:

CHENG-LAN LV;
JUAN LI

Publication type:

Article

Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine.

Published in:

Molecular & Clinical Oncology, 2017, v. 7, n. 4, p. 525, doi. 10.3892/mco.2017.1364

By:

CHEN CHEN;
HONGMIN HE

Publication type:

Article

An Unusual Cause of Altered Mental Status in Multiple Myeloma: An Extraosseous Manifestation.

Published in:

Hawaii Journal of Medicine & Public Health, 2016, v. 75, n. 4, p. 109

By:

Jaruvongvanich, Veeravich;
Spanuchart, Ittikorn;
O-charoen, Pichaya;
Kitamura, Christian;
Sumida, Lauren;
Roytman, Marina

Publication type:

Article

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data.

Published in:

Frontiers in Pharmacology, 2020, v. 11, p. N.PAG, doi. 10.3389/fphar.2020.561601

By:

He, Jingsong;
He, Donghua;
Han, Xiaoyan;
Zheng, Gaofeng;
Wei, Guoqing;
Zhao, Yi;
Yang, Yang;
Wu, Wenjun;
Fu, Jiaping;
Shou, Lihong;
Kong, Hongwei;
Huang, He;
Cai, Zhen

Publication type:

Article

Molecular Insight Into the IRE1α-Mediated Type I Interferon Response Induced by Proteasome Impairment in Myeloid Cells of the Brain.

Published in:

Frontiers in Immunology, 2019, v. 10, p. 1, doi. 10.3389/fimmu.2019.02900

By:

Studencka-Turski, Maja;
Çetin, Gonca;
Junker, Heike;
Ebstein, Frédéric;
Krüger, Elke

Publication type:

Article

Editorial: Immunotherapy in Multiple Myeloma.

Published in:

2019

By:

Giuliani, Nicola;
Malavasi, Fabio

Publication type:

Editorial

Epidemiology and predictors of hyponatremia in a contemporary cohort of patients with malignancy: a retrospective cohort study.

Published in:

Clinical Kidney Journal, 2023, v. 16, n. 11, p. 2072, doi. 10.1093/ckj/sfad189

By:

Murashima, Miho;
Ambe, Kaori;
Aoki, Yuka;
Kasugai, Takahisa;
Tomonari, Tatsuya;
Ono, Minamo;
Mizuno, Masashi;
Tohkin, Masahiro;
Hamano, Takayuki

Publication type:

Article